Switch to:
Also traded in: Canada, Germany, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.78
VBIV's Cash-to-Debt is ranked lower than
83% of the 1046 Companies
in the Global Biotechnology industry.

( Industry Median: 55.72 vs. VBIV: 0.78 )
Ranked among companies with meaningful Cash-to-Debt only.
VBIV' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29  Med: No Debt Max: No Debt
Current: 0.78
0.29
No Debt
Equity-to-Asset 0.71
VBIV's Equity-to-Asset is ranked higher than
54% of the 767 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. VBIV: 0.71 )
Ranked among companies with meaningful Equity-to-Asset only.
VBIV' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.67  Med: 0.79 Max: 0.93
Current: 0.71
0.67
0.93
Debt-to-Equity 0.20
VBIV's Debt-to-Equity is ranked higher than
58% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: 0.26 vs. VBIV: 0.20 )
Ranked among companies with meaningful Debt-to-Equity only.
VBIV' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03  Med: 0.2 Max: 1.01
Current: 0.2
0.03
1.01
Debt-to-EBITDA -0.35
VBIV's Debt-to-EBITDA is ranked lower than
99.99% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 1.94 vs. VBIV: -0.35 )
Ranked among companies with meaningful Debt-to-EBITDA only.
VBIV' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.49  Med: -0.49 Max: -0.35
Current: -0.35
-0.49
-0.35
Piotroski F-Score: 3
Altman Z-Score: 2.23
Beneish M-Score: -2.36
WACC vs ROIC
15.99%
-50.72%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -4362.28
VBIV's Operating Margin % is ranked lower than
88% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -105.96 vs. VBIV: -4362.28 )
Ranked among companies with meaningful Operating Margin % only.
VBIV' s Operating Margin % Range Over the Past 10 Years
Min: -4534.67  Med: -4534.67 Max: -4362.28
Current: -4362.28
-4534.67
-4362.28
Net Margin % -4469.72
VBIV's Net Margin % is ranked lower than
88% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -92.13 vs. VBIV: -4469.72 )
Ranked among companies with meaningful Net Margin % only.
VBIV' s Net Margin % Range Over the Past 10 Years
Min: -4469.72  Med: -4234.49 Max: -4234.49
Current: -4469.72
-4469.72
-4234.49
ROE % -48.05
VBIV's ROE % is ranked lower than
54% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: -39.05 vs. VBIV: -48.05 )
Ranked among companies with meaningful ROE % only.
VBIV' s ROE % Range Over the Past 10 Years
Min: -60.18  Med: -21.99 Max: -2.88
Current: -48.05
-60.18
-2.88
ROA % -37.88
VBIV's ROA % is ranked lower than
54% of the 1052 Companies
in the Global Biotechnology industry.

( Industry Median: -32.93 vs. VBIV: -37.88 )
Ranked among companies with meaningful ROA % only.
VBIV' s ROA % Range Over the Past 10 Years
Min: -60.05  Med: -20.08 Max: -2.88
Current: -37.88
-60.05
-2.88
ROC (Joel Greenblatt) % -1717.71
VBIV's ROC (Joel Greenblatt) % is ranked lower than
68% of the 1014 Companies
in the Global Biotechnology industry.

( Industry Median: -432.52 vs. VBIV: -1717.71 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
VBIV' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -10556.7  Med: -25.72 Max: -4.57
Current: -1717.71
-10556.7
-4.57
3-Year EBITDA Growth Rate -10.60
VBIV's 3-Year EBITDA Growth Rate is ranked lower than
66% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. VBIV: -10.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
VBIV' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -54.7  Med: -0.8 Max: 187.8
Current: -10.6
-54.7
187.8
3-Year EPS without NRI Growth Rate -5.30
VBIV's 3-Year EPS without NRI Growth Rate is ranked lower than
55% of the 683 Companies
in the Global Biotechnology industry.

( Industry Median: -1.10 vs. VBIV: -5.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
VBIV' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -5.3 Max: 217.3
Current: -5.3
0
217.3
GuruFocus has detected 1 Warning Sign with VBI Vaccines Inc VBIV.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» VBIV's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

VBIV Guru Trades in

Q3 2016

VBIV Guru Trades in Q3 2016

Jim Simons 14,200 sh (New)
» More
Q4 2016

VBIV Guru Trades in Q4 2016

Jim Simons Sold Out
» More
Q4 2017

VBIV Guru Trades in Q4 2017

Jim Simons 91,500 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with VBIV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 3741
Compare:NAS:CASI, OCSE:ORPHA, XKRX:115180, NAS:FWP, NAS:KIN, NAS:FOMX, NAS:VCEL, NAS:NERV, OSTO:BIOA B, NAS:NBRV, TSX:RVX, TSXV:COB.U, TSX:NEPT, NAS:VTL, XSWX:EVE, NAS:CASC, ASX:MVF, NAS:VTVT, XPAR:TNG, XTER:B8F » details
Traded in other countries:VBV.Canada, LO91.Germany, SVACD.USA,
Headquarter Location:USA
VBI Vaccines Inc is a biopharmaceutical company. It is engaged in developing novel technologies that seek to expand vaccine protection in large underserved markets.

VBI Vaccines Inc is a US-based commercial-stage, the biopharmaceutical company which is engaged in developing next-generation vaccines to address unmet needs in infectious disease and immuno-oncology. The company manufactures Sci-B-Vac product which is a hepatitis B (HBV) vaccine for adults, children, and newborns. Its products include Virus-Like Particle which is vaccine platform which allows for the design of enveloped virus-like particle vaccines that closely mimic the target viruses. The company operates through the single segment being Developing vaccines to address unmet needs in infectious disease and immuno-oncology.

Top Ranked Articles about VBI Vaccines Inc

VBI Vaccines Announces Changes to its Board of Directors
VBI Vaccines Announces Changes to its Board of Directors
VBI Vaccines Announces Dosing of First GBM Patient in Phase 1/2a Clinical Study of VBI-1901
VBI Vaccines Announces Initiation of Phase 3 Clinical Program for Sci-B-Vac® Hepatitis B Vaccine
VBI Vaccines to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at SITC 2017
Largest Insider Trades of the Week Dollar Tree, Exelon among stocks sold by insiders
The GuruFocus All-In-One Screener can be used to find insider trades from the past week. Under the Insiders tab, change the settings for All Insider Buying to “$200,000+,” the duration to “October 2017” and “November 2017” and All Insider Sales to “$5,000,000+." Read more...
VBI Vaccines Strengthens Board of Directors with Appointment of Ran Nussbaum
VBI Vaccines Announces Closing of Public Offering and Concurrent Registered Direct Offering of Common Shares
VBI Vaccines Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Upsized Registered Direct Offering for Aggregate Proceeds of $71.9 Million

Ratios

vs
industry
vs
history
PB Ratio 2.55
VBIV's PB Ratio is ranked higher than
69% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. VBIV: 2.55 )
Ranked among companies with meaningful PB Ratio only.
VBIV' s PB Ratio Range Over the Past 10 Years
Min: 1.36  Med: 2.58 Max: 8.5
Current: 2.55
1.36
8.5
PS Ratio 187.02
VBIV's PS Ratio is ranked lower than
89% of the 731 Companies
in the Global Biotechnology industry.

( Industry Median: 11.11 vs. VBIV: 187.02 )
Ranked among companies with meaningful PS Ratio only.
VBIV' s PS Ratio Range Over the Past 10 Years
Min: 142.67  Med: 284.09 Max: 1400
Current: 187.02
142.67
1400
EV-to-EBIT -6.87
VBIV's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.83 vs. VBIV: -6.87 )
Ranked among companies with meaningful EV-to-EBIT only.
VBIV' s EV-to-EBIT Range Over the Past 10 Years
Min: -7.6  Med: -4.5 Max: -2.4
Current: -6.87
-7.6
-2.4
EV-to-EBITDA -7.03
VBIV's EV-to-EBITDA is ranked lower than
99.99% of the 285 Companies
in the Global Biotechnology industry.

( Industry Median: 20.69 vs. VBIV: -7.03 )
Ranked among companies with meaningful EV-to-EBITDA only.
VBIV' s EV-to-EBITDA Range Over the Past 10 Years
Min: -7.8  Med: -4.6 Max: -2.4
Current: -7.03
-7.8
-2.4
EV-to-Revenue 299.62
VBIV's EV-to-Revenue is ranked lower than
87% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 12.21 vs. VBIV: 299.62 )
Ranked among companies with meaningful EV-to-Revenue only.
VBIV' s EV-to-Revenue Range Over the Past 10 Years
Min: 142.1  Med: 286.8 Max: 1305.1
Current: 299.62
142.1
1305.1
Current Ratio 1.03
VBIV's Current Ratio is ranked lower than
88% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. VBIV: 1.03 )
Ranked among companies with meaningful Current Ratio only.
VBIV' s Current Ratio Range Over the Past 10 Years
Min: 0.04  Med: 3.31 Max: 316.56
Current: 1.03
0.04
316.56
Quick Ratio 0.97
VBIV's Quick Ratio is ranked lower than
86% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.86 vs. VBIV: 0.97 )
Ranked among companies with meaningful Quick Ratio only.
VBIV' s Quick Ratio Range Over the Past 10 Years
Min: 0.04  Med: 3.3 Max: 316.56
Current: 0.97
0.04
316.56
Days Inventory 61.05
VBIV's Days Inventory is ranked higher than
73% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: 126.17 vs. VBIV: 61.05 )
Ranked among companies with meaningful Days Inventory only.
VBIV' s Days Inventory Range Over the Past 10 Years
Min: 41.26  Med: 41.26 Max: 61.05
Current: 61.05
41.26
61.05
Days Sales Outstanding 86.89
VBIV's Days Sales Outstanding is ranked lower than
67% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: 65.03 vs. VBIV: 86.89 )
Ranked among companies with meaningful Days Sales Outstanding only.
VBIV' s Days Sales Outstanding Range Over the Past 10 Years
Min: 6.66  Med: 6.66 Max: 86.89
Current: 86.89
6.66
86.89
Days Payable 233.91
VBIV's Days Payable is ranked higher than
85% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 59.19 vs. VBIV: 233.91 )
Ranked among companies with meaningful Days Payable only.
VBIV' s Days Payable Range Over the Past 10 Years
Min: 200.65  Med: 830.33 Max: 1460
Current: 233.91
200.65
1460

Buy Back

vs
industry
vs
history
5-Year Yield-on-Cost % 6.30
VBIV's 5-Year Yield-on-Cost % is ranked higher than
86% of the 317 Companies
in the Global Biotechnology industry.

( Industry Median: 1.56 vs. VBIV: 6.30 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
VBIV' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 6.3
3-Year Average Share Buyback Ratio -100.00
VBIV's 3-Year Average Share Buyback Ratio is ranked lower than
92% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. VBIV: -100.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
VBIV' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -100  Med: -20.7 Max: 0
Current: -100
-100
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.66
VBIV's Price-to-Median-PS-Value is ranked higher than
71% of the 629 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. VBIV: 0.66 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
VBIV' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.01  Med: 0.02 Max: 3.95
Current: 0.66
0.01
3.95
Earnings Yield (Greenblatt) % -14.58
VBIV's Earnings Yield (Greenblatt) % is ranked lower than
64% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -7.37 vs. VBIV: -14.58 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
VBIV' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -41.8  Med: -22.3 Max: -13.1
Current: -14.58
-41.8
-13.1

More Statistics

Revenue (TTM) (Mil) $0.80
EPS (TTM) $ -0.91
Beta2.01
Short Percentage of Float1.97%
52-Week Range $3.04 - 6.60
Shares Outstanding (Mil)63.80

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}